跳至主要内容
临床试验/NCT05510804
NCT05510804Unknown不适用

Ambulante Leitlinienkonforme Intervention im Selbstmanagement für Angststörungen (ALISA)

Bartosz of Zurowski4 个研究点 分布在 1 个国家目标入组 222 人开始时间: 2020年3月3日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
222
试验地点
4
主要终点
Change in Beck Anxiety Inventory (BAI)

研究概览

简要总结

Primary aim is to evaluate the efficacy of a (minimally) therapist-guided app-based psychotherapy with virtual reality exposure therapy (ALISA) in participants with agoraphobia with or without panic disorder, social anxiety disorder or panic disorder. Participants are diagnosed applying a structured clinical interview by qualified psychologists and then they are randomly allocated to either the intervention group (ALISA) or a control group, receiving supportive psychotherapy while on a waiting list for a structured therapy programme. The investigators hypothesize that participants receiving ALISA compared to controls will present lower levels of anxiety and a higher quality of life at six-month follow-up after start of the intervention, according to Beck Anxiety Inventory (BAI, primary outcome measure) and WHO-QoL, respectively.

详细描述

Primary aim is to evaluate the efficacy of a (minimally) therapist-guided app-based psychotherapy with virtual reality exposure therapy (ALISA) in participants with agoraphobia (with or without panic disorder), social anxiety disorder or panic disorder. The intervention has been developed by Sympatient GmbH in cooperation with the University of Luebeck, Dept. of Psychiatry. It consists of scheduled therapist assistance, a smartphone-based application consisting of eight CBT-based courses including instructive therapist videos, questionnaires and VR exposure scenarios presented via VR goggles as well as interoceptive exposures.

Participants are diagnosed according to a structured clinical interview (SCID) by experienced and trained clinical psychologists. Then they are randomly allocated to either the intervention group (ALISA) or a control group offered supportive psychotherapy while being on a waiting list for a structured therapy programme of an outpatient unit for patients with anxiety disorders. The investigators hypothesize that participants receiving ALISA - as compared to controls - will present lower levels of anxiety and a higher quality of life at 6-month follow-up after start of the intervention, according to Beck Anxiety Inventory (BAI, primary outcome measure) and WHO-QoL (L-1), respectively. Furthermore, the investigators hypothesize that the reduction of anxiety (ANOVA; group x time) can be shown at 1-year follow up. The investigators expect ALISA to be effective in each of the three disorder-specific therapy schedules (social phobia, panic disorder, agoraphobia w/without panic disorder). Therefore, disorder-specific symptom scales have been additionally adopted: Panic and Agoraphobia Scale (PAS) and Liebowitz Social Phobia Scale. Co-morbid depression and global functioning will be assessed using CGI and GAF as secondary outcome measures, respectively.

The allocation to the groups was conducted on the basis of random numbers generated by Microsoft Excel 2013 and with the restriction that the ratio of intervention to control group participants was 2:1. This unequal randomization was chosen for ethical reasons including a more reliable assessment of adverse events in the intervention group with a higher power. A planned sample size of n = 41 for each of the three diagnoses in the intervention group and n = 21 for each of the three diagnoses in the control group was calculated to detect a significant difference with an effect size of Cohens´s d = 0.9 with a probability of 90% and α = 2.5. Adding an estimated dropout-rate of 20%, each diagnosis group should include n = 49 participants in the intervention group and n = 25 in the control group, resulting in a total of N = 222 participants. (Multiple) imputation will be applied to deal with missing data. Results of Intention to treat analyses and following per protocol analyses will be reported.

Using records of cooperating health insurances, a health economic analysis of the intervention will be performed. Given that patients with untreated anxiety disorders show a markedly increased use of health system, a successful reduction of anxiety, once proven, should have an impact on patient's use of the health system in general (exploratory analysis)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary diagnosis: Agoraphobia w/without PD (F 40.0, F40.01) OR Panic disorder (F41.0) OR Social anxiety disorder (phobia) (F40.1)
  • Smartphone availability

排除标准

  • history of stroke or heart attack
  • angina pectoris
  • cardiac arrhythmia
  • untreated high blood pressure
  • severe asthma or chronic obstructive pulmonary disease (COPD)
  • (supposed) pregnancy
  • severe visual impairment
  • severe nausea and/or vestibular impairment
  • neuropsychiatric condition (i.e. dementia)
  • psychiatric disorder associated with substance abuse
  • psychotic disorder
  • severe episode of major depression or manic episode
  • suicidal ideation or behavior

结局指标

主要结局

Change in Beck Anxiety Inventory (BAI)

时间窗: 6 months after inclusion

standard self-report instrument (21 items) for anxiety applicable in all three disorders investigated

次要结局

  • Change in WHO QoL L-1(12 months after inclusion)
  • Change in Global Assessment of Functioning (GAF)(through intervention completion, on average month 3)
  • Change in Beck Anxiety Inventory (BAI)(12 months after inclusion)
  • Change in Clinical Global Impression CGI(through intervention completion, on average month 3)

研究者

发起方
Bartosz of Zurowski
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Bartosz of Zurowski

Principal Investigator

University of Luebeck

研究点 (4)

Loading locations...

相似试验